HER2 expression varies by tumor location and type. All patients with advanced gastric or gastroesophageal junction cancer should be tested for HER2 status, preferably using IHC initially. Due to the unique characteristics of gastric cancer, specific testing/scoring guidelines should be adhered to.
No takes yet. Share an insight, caveat, or question.
Cutsem et al. (2014) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: